Increased levels of t-tau, p-tau, and Aβ42 in plasma/serum neurally derived blood exosomes were demonstrated to be an early biomarker for AD and cognitive decline progression (Fiandaca et al., 2015). The gene discussed is MAPT; the disease is Alzheimer disease.